From Local Powerhouses to Global Players: China’s Pharmaceutical CDMO Industry in the Era of Specialization and Innovation

View our Complimentary Blue Book

The pharmaceutical industry chain is becoming increasingly specialized, refined, and customized. Contract Development and Manufacturing Organizations (CDMOs), which represent the pharmaceutical contract outsourcing service sector, have emerged and quickly become an essential part of the global pharmaceutical industry. The rise of the innovative drug sector has created vast room for the development of the CDMO industry. CDMO companies, supported by their large-scale manufacturing capabilities and high-value R&D and production processes, have become key partners to pharmaceutical companies, supporting them across the entire process from drug concept to market launch, and from process development to large-scale production. In recent years, Chinese CDMO companies, driven by a global expansion strategy, have actively entered international markets. Through initiatives such as setting up overseas R&D centers and building production bases that comply with international standards, they have deeply participated in global pharmaceutical industry competition and collaboration, contributing new momentum to its growth.

Download this complimentary Blue book to discover:

R

Analysis of Background and Development History:

An in-depth look at the origins and evolutionary trajectory of the CDMO industry, tracing its growth from early outsourcing models to today’s globalized, technology-driven ecosystem.

R

Analysis of Drivers Behind CDMO Industry Growth:

A multidimensional exploration of the forces propelling the CDMO sector, including technological innovation (e.g., AI, continuous manufacturing), policy support (e.g., MAH system in China), capital investments, and the rising demand for specialized services in biologics and advanced therapies.

R

Analysis of Global and China Pharmaceutical CDMO Market:

A comprehensive examination of market sizes, growth rates, and competitive dynamics across regions, highlighting China’s rising role in the global pharmaceutical value chain.

R

Analysis of Multi-faceted Exploration of the Future Development trends:

A forward-looking assessment of how CDMOs will adapt to emerging trends, including technological disruptions, market shifts, and strategic pivots.

View Blue Book Now

Default PDF Reader

Fullscreen Mode

Register to Download the Blue Book To-go

"*" indicates required fields

Name*

Job Title*

Company*

Phone*

Business Email*

Country*

Company Size*

CAPTCHA

Email

This field is for validation purposes and should be left unchanged.

60 YEARS OF INSIGHTS

Our Global Initiatives



Empower innovation, echoing the voices of emerging technologies and companies, shaping progressive pathways in a dynamic market.



Growth Opportunity content distribution to offer a one-stop platform providing a 360-degree global perspective on the latest industry developments, events, and advancements.



Partner to equip your company with insights and enable capitalization on growth opportunities, ensuring your queries are addressed in a global marketplace.

Download Blue Book Now

ABOUT THE ANALYST

Evin WANG

Project Manager of Frost & Sullivan Greater China, participated in market research projects，focusing on medicine, medical device and medical service.

About Our Firm

Frost & Sullivan

Frost & Sullivan has partnered with clients for more than 60 years, developing growth strategies centered on innovation, disruptive technologies, emerging markets, Mega Trends, and new business models.